Given that CD163+ cells have been shown to reduce T-cell abundance [17,18,19], a double labeling procedure using CD163 (brown) and the anti-tumor effector T cell marker CD8 (red), was carried out on the entire patient cohort (Table S3, Figure 3a). The gene discussed is CD8A; the disease is neoplasm.